Document is current
Any future updates will be listed below
-
Authors
Moein, Anita
Jin, Jin Y.
Wright, Matthew R.
Wong, Harvey
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02340221 at ClinicalTrials.govnct01296555 at ClinicalTrials.govDocuments that mention this clinical trial
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
https://doi.org/10.1007/s00280-024-04690-4
Documents that mention this clinical trial
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2014.08.024
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
https://doi.org/10.1007/s00280-024-04690-4
-
Funding
Funding for this research was provided by:
This work was supported by Genentech Inc., a member of the Roche group.
- License Information
-
More Information
Article History
Received: 3 February 2024
Accepted: 14 June 2024
First Online: 27 June 2024
Declarations
:
: A.M., J.Y.J., M.R.W. are Genentech employees and Roche shareholders. H.W. is Faculty of Pharmaceutical Sciences at the University of British Columbia working under contract with Genentech.
: A.M., J.Y.J., M.W. are Genentech employees and Roche shareholders. H.W. is Faculty of Pharmaceutical Sciences at the University of British Columbia working under contract with Genentech.
: NCT02340221 and NCT01296555 studies were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Prior to enrollment, written informed consent was acquired from all patients, in alignment with the approved protocols from the ethics committees at each study site.
